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tuberculosis (TB-HAART): a prospective, international,
randomised, placebo-controlled trial. Lancet Infect Dis. 2014,Dear Editor,
The  THRio study was  a cluster randomized trial evaluating the
impact  of training health care providers at 29 health clinics
linked  to the Rio the Janeiro City Health Secretariat to follow
the  Brazilian guidelines to treat latent TB infection among
people  living with HIV/AIDS (PLWHA).1 THRio included all
current  and new HIV/AIDS patients during a 4-year period
independent of their CD4 cell counts, capturing data from
medical  charts. Our recent analysis published in the Brazilian
Journal  of Infectious Disease used data from the THRio
cohort to compare simultaneous or deferred HAART in those
diagnosed  with TB and included all patients regardless of
their  CD4 count at the time of their TB episode.2 Our ﬁndings
of  a greater risk of death among patients with deferred
HAART were  consistent with clinical trials in Africa included
predominantly patients with more  advanced immune
compromise.3,4
Mﬁnanga et al. recently reported a non-signiﬁcant dif-
ference  between early and deferred HAART (waiting for
completion of 6-month TB therapy course) with enrollment
limited to those with CD4 counts over 220 cells/mm3 at time of
TB  diagnosis, suggesting that HAART can be delayed in PLWHA
with  relatively preserved immunity.5 However, all other trials
and  cohort data to date have shown beneﬁt from early HAART,
including  ours, and have included patients with very low CD4
cell  counts.
Mﬁnanga and colleagues proposed a change in the
WHO  guidelines, given their ﬁndings and their strength
of  evidence (placebo-controlled RCT), which should be
better  evaluated given other beneﬁts derived from early
DOI of original article: http://dx.doi.org/10.1016/j.bjid.2014.06.003.HAART initiation, at both the individual and population
level.
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